<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/353185</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Confirmatory Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Systems Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>In silico</italic> modeling and simulation of neuroendocrine-immune modulation through adrenergic and 17&#x03B2;-estradiol receptors in lymphocytes show differential activation of cyclic adenosine monophosphate (cAMP)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9555-7394</contrib-id>
<name><surname>Priyanka</surname><given-names>H. P.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1151-7828</contrib-id>
<name><surname>Thiyagaraj</surname><given-names>A.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Krithika</surname><given-names>G.</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hima</surname><given-names>L.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6912-4835</contrib-id>
<name><surname>Hopper</surname><given-names>W.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>ThyagaRajan</surname><given-names>S.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University</institution>, Kattankulathur 603203, <country>India</country>
</aff>
<aff id="a2"><label>2</label><institution>Department of Bioinformatics, School of Bioengineering, SRM University</institution>, Kattankulathur 603203, <country>India</country>
</aff>
<aff id="a3"><label>3</label><institution>Centre of Advanced Study in Crystallography and Biophysics, University of Madras Guindy Campus</institution>, Chennai 600025, <country>India</country>
</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>1</label>Corresponding author: Hannah P. Priyanka, Institute of Advanced Research in Health Sciences, Tamil Nadu Government Multi Super Speciality Hospital, Omandurar Government Estate, Chennai 600002, Tamil Nadu, INDIA, Email: <email>hannahpriyanka@gmail.com</email>, Phone: 91-9841883355</corresp>
</author-notes>
<pub-date pub-type="epub"><year>2018</year></pub-date>
<elocation-id>353185</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>21</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>6</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="353185.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Sympathetic innervation of lymphoid organs and presence of 17&#x03B2;-estradiol and adrenergic receptors (ARs) on lymphocytes suggests that sympathetic stimulation and hormonal activation may influence immune functions. Simulation of these pathways may help to understand the dynamics of neuroendocrine-immune modulation at the cellular and molecular level.</p>
<p>Dose&#x002D; and receptor-dependent effects of 17&#x03B2;-estradiol and AR sub-type-specific agonists were established in vitro on lymphocytes from young male Sprague-Dawley rats and modeled in silico using MATLAB Simbiology toolbox. Kinetic principles were assigned to define receptor-ligand dynamics and state/time plots were obtained using Ode15s solvers at different time intervals for key regulatory molecules. Comparisons were drawn between in silico and in vitro data for validating the constructed model with sensitivity analysis of key regulatory molecules to assess their individual impacts on the dynamics of the system. Finally docking studies were conducted with key ligands 17&#x03B2;-estradiol and norepinephrine to understand the mechanistic principles underlying their interactions.</p>
<p>Adrenergic activation triggered pro-apoptotic signals while 17&#x03B2;-estradiol enhanced survival signals showing contradictory effects as observed in vitro. Treatment of lymphocytes with 17&#x03B2;-estradiol shows ten-fold increase in survival signals concentration-dependently manner. cAMP activation is crucial for the activation of survival signals through p-ERK (Extracellular Signal-Regulated Kinase) and p-CREB (cAMP Responsive Element Binding (protein). Inhibition of p-ERK by norepinephrine and &#x03B2;2-AR by 17&#x03B2;-estradiol indicate direct influence on the downstream signals altering apoptotic v/s survival signals.</p>
<p>Thus, the cross-talk between 17&#x03B2;-estradiol and adrenergic signaling pathways determines lymphocyte functions in a receptor subtype&#x002D; and co-activation-dependent manner in health and disease.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Key words</title>
<kwd>Immunomodulation</kwd>
<kwd>T-cell</kwd>
<kwd>norepinephrine</kwd>
<kwd>17&#x03B2;-estradiol</kwd>
<kwd>p-ERK</kwd>
<kwd>IFN-&#x03B3;</kwd>
</kwd-group>
<counts>
<page-count count="38"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<label>1.0</label>
<title>Introduction</title>
<p>The neuroendocrine-immune network is a complex inter-regulatory system with wide plasticity in order to maintain systemic homeostasis [<xref ref-type="bibr" rid="c1">1</xref>&#x2013;<xref ref-type="bibr" rid="c3">3</xref>]. In females, the cyclic fluctuations in the levels of gonadal hormones especially, 17&#x03B2;-estradiol affect the functioning of immune effector cells by binding to specific receptors [<xref ref-type="bibr" rid="c4">4</xref>&#x2013;<xref ref-type="bibr" rid="c7">7</xref>].</p>
<p>In the periphery, <italic>in vitro</italic> and <italic>in vivo</italic> 17&#x03B2;-estradiol-stimulation has been shown to enhance splenocyte proliferation and cytokine production through the alteration of specific signaling molecules [<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c8">8</xref>]. In the resting state, the close apposition of T-lymphocytes in direct synaptic association with sympathetic noradrenergic (NA) nerve fibers that innervate the lymphoid organs renders them highly responsive to norepinephrine [NE; <xref rid="c7" ref-type="bibr">7</xref>, <xref rid="c9" ref-type="bibr">9</xref>&#x2013;<xref rid="c13" ref-type="bibr">13</xref>]. Since both 17&#x03B2;-estradiol and NE mediate their effects on lymphocytes through their specific receptors, their down-stream effects are dependent upon the kinetic parameters that govern receptor-ligand interactions [<xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c14">14</xref>&#x2013;<xref ref-type="bibr" rid="c16">16</xref>]. Previous studies from our laboratory and others have shown that both 17&#x03B2;-estradiol and norepinephrine-induced signaling cascades involve similar signaling molecules (p-ERK, p-CREB, cAMP and p-Akt) in modulating the expression of similar cytokines (IFN-&#x03B3; and IL-2) thereby, altering cell-mediated immune functions [<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c17">17</xref>&#x2013;<xref ref-type="bibr" rid="c18">18</xref>]. Thus, the scope of cross-talk between the two pathways during multiple ligand-receptor interactions is infinite. Considering that NE can bind to &#x03B1;1-/&#x03B1;2&#x002D; or &#x03B2;1-/&#x03B2;2-/&#x03B2;3-adrenoceptors (AR) on lymphocytes and 17&#x03B2;-estradiol can bind to cytosolic (cERs) or nuclear (nERs) 17&#x03B2;-estradiol receptors and initiate signals that target similar down-stream signaling molecules, the underlying kinetic parameters will influence the outcome of the cross-talk through synergistic, additive or diminutive effects. Hence in this study, we have created a dynamic model of resting lymphocyte functions in the presence of 17&#x03B2;-estradiol and/or NE using kinetic principles that govern receptor-ligand activation from secondary data with concentration and down-stream signaling data from <italic>in vitro</italic> studies published from our laboratory. Also, in an attempt to understand the multiple levels of interactions between these two pathways, we have also conducted docking studies of 17&#x03B2;-estradiol with the &#x03B2;2-AR and NE with the key signaling molecule in 17&#x03B2;-estradiol signaling cascade p-ERK.</p>
</sec>
<sec id="s2">
<label>2.0</label>
<title>Methods</title>
<sec id="s2a">
<label>2.1</label>
<title>Model building</title>
<p>The model was built using both primary and secondary data sources. The dose&#x002D; and receptor-dependent effects of 17&#x03B2;-estradiol and AR sub-type-specific agonists were established <italic>in vitro</italic> on lymphocytes from young male Sprague-Dawley rats in previous studies published by our laboratory [<xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c18">18</xref>]. In these studies, the concentration of the signaling molecules, cytokines, and other secondary molecules was determined using ELISA and this data was used to construct the model (<xref ref-type="table" rid="tbl1a">Tables 1</xref>, <xref rid="tbl2a" ref-type="table">2</xref>). The possible cross-talk pathway was mapped using receptor-specific inhibitors and inhibitors of signal transduction molecules and was modeled <italic>in silico</italic> using MATLAB Simbiology toolbox. Receptor-ligand dynamics were defined based on kinetic principles from available literature and previous studies from our laboratory. State versus time plots were obtained using Ode15s solvers at 1ns-1s time intervals in accordance with neurotransmitter kinetics and at 24-72 hrs for long-term effects on lymphocyte functions. Comparisons were drawn between <italic>in silico</italic> and <italic>in vitro</italic> data for validating the constructed model. Sensitivity analysis was performed on key regulatory molecules to assess their individual impacts on the dynamics of the system.</p>
</sec>
<sec id="s2a1">
<label>2.1.1</label>
<title>Model</title>
<p>The model was built to show an interconnected network of four signaling pathways on the basis of in vitro studies conducted in our laboratory including:
<list list-type="order">
<list-item><p>&#x03B1;1-adrenoceptor signaling [<xref rid="c17" ref-type="bibr">17</xref>]; (<xref ref-type="table" rid="tbl1a">Table 1A</xref>)</p></list-item>
<list-item><p>&#x03B1;2-adrenoceptor signaling [<xref rid="c17" ref-type="bibr">17</xref>]; (<xref ref-type="table" rid="tbl1a">Table 1B</xref>)</p></list-item>
<list-item><p>&#x03B2;2-adrenoceptor signaling [<xref rid="c18" ref-type="bibr">18</xref>]; (<xref ref-type="table" rid="tbl1a">Table 1C</xref>)</p></list-item>
<list-item><p>17&#x03B2;-estradiol signaling through ERs and GPCRs [<xref rid="c4" ref-type="bibr">4</xref>]; (<xref ref-type="table" rid="tbl1b">Table 1D</xref>) and their respective kinetic parameters outlined in <xref ref-type="table" rid="tbl2a">Table 2</xref>.</p></list-item>
</list>
</p>
<table-wrap id="tbl1a" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><p>Reaction table and kinetics for &#x03B1;1-adrenoceptor signaling (1A), &#x03B1;2-adrenoceptor signaling (1B), &#x03B2;2-adrenoceptor signaling (1C) and 17&#x03B2;-estradiol signaling through ERs and GPCRs (1D).</p></caption>
<graphic xlink:href="353185_tbl1a.tif"/>
</table-wrap>
<table-wrap id="tbl1b" orientation="portrait" position="float">
<graphic xlink:href="353185_tbl1b.tif"/>
</table-wrap>
<table-wrap id="tbl1c" orientation="portrait" position="float">
<graphic xlink:href="353185_tbl1c.tif"/>
</table-wrap>
<table-wrap id="tbl2a" orientation="portrait" position="float">
<label>Table 2:</label>
<caption><p>Receptor Binding maxima and Kd values (A), Signaling Molecule concentrations (B) and Ligand concentrations (C) as incorporated in the model.</p></caption>
<graphic xlink:href="353185_tbl2a.tif"/>
</table-wrap>
<table-wrap id="tbl2b" orientation="portrait" position="float">
<graphic xlink:href="353185_tbl2b.tif"/>
</table-wrap>
</sec>
<sec id="s2b">
<label>2.2</label>
<title>Simulations</title>
<p>Simulations were performed using Ode15s solvers at different time points depending upon the signals studied. For signaling molecules including p-ERK, p-Akt, p-CREB, and cAMP, simulations were performed for 0.05 seconds in order to capture the rapid neurotransmitter/steroid hormone-mediated transduction. For the cytokines including IL-2 and IFN-&#x03B3;, the simulations were performed for 24 hours. For antioxidant enzymes and ROS/RNS the simulations were performed up to 3000 seconds. Finally, for survival v/s apoptotic signals, the simulations were carried out for 72 hours.</p>
</sec>
<sec id="s2c">
<label>2.3</label>
<title>Sensitivity Analysis</title>
<p>Key regulatory molecules were scanned and their sensitivities were analyzed at 24 hours for each of the ligands used. In this case, phenylephrine-, clonidine-, terbutaline-, and 17&#x03B2;-estradiol-mediated signals were scanned for their sensitivities in two groups: (a) molecular markers (p-ERK, p-CREB, p-Akt and cAMP) and (b) cytokines (IL-2 and IFN-&#x03B3;).</p>
</sec>
<sec id="s2d">
<label>2.4</label>
<title>Docking</title>
<p>Molecular docking was performed by keeping the ERK molecule or the &#x03B2;2-AR molecule rigid and ligand (NE or 17&#x03B2;-estradiol) flexible (Rigid Docking). This resulted in different conformations in each run and the best conformer which fits with lowest binding energy (kcal/mol) was chosen and written as a PDB file using UCSF Chimera. Auto Dock4.2.6 was used to automatically dock the ligands to the enzyme. In this version the windows platform, cygwin was used for our analyses. The enzyme/receptor molecule was loaded and stored as a &#x2024;pdb file after assigning hydrogen bonds and kollman charges. The investigation ligands were loaded and their torsions along with rotatable bonds were assigned and the file saved as ligand &#x2024;pdbqt. Grid menu is toggled, after loading enzyme &#x2024;pdbqt the map files were selected directly with setting up grid points with 80 &#x00D7; 106 &#x00D7; 90 dimensions for the searching of ligand within the active site of the enzyme molecule. This way the grid parameter files were created. The docking parameter files were then set up with search parameter as genetic algorithm and docking parameter utilizing Lamarckian genetic algorithm. Following up of grid parameter files (gpf) and docking log files (dlg), the command prompt was toggled and commands were typed in stepwise for autogrid and autodock execution. The docked structures were generated after maximum number of evaluations using UCSF Chimera.</p>
</sec>
</sec>
<sec id="s3">
<label>3.0</label>
<title>Results</title>
<sec id="s3a">
<label>3.1</label>
<title>17&#x03B2;-estmdiol treatment alters signaling molecule expression in lymphocytes stimulated with adrenergic agonists</title>
<p>Simulation of lymphocytes with adrenergic agonists, terbutaline, clonidine, and phenylephrine (<xref ref-type="fig" rid="fig2">Fig. 2A</xref>), or 17&#x03B2;-estradiol (<xref ref-type="fig" rid="fig2">Fig. 2B</xref>) or both (<xref ref-type="fig" rid="fig2">Fig. 2C</xref>) significantly alters the expression of p-ERK, p-CREB, p-Akt, and cAMP. State v/s time diagrams at 0.05 seconds show significantly enhanced p-CREB and p-ERK expression alone upon stimulation with adrenergic agonists (<xref ref-type="fig" rid="fig2">Fig. 2A</xref>). Stimulation with 17&#x03B2;-estradiol in the absence of adrenergic agonists (<xref ref-type="fig" rid="fig2">Fig. 2B</xref>) or with adrenergic agonists (<xref ref-type="fig" rid="fig2">Fig. 2C</xref>) significantly enhanced cAMP, p-ERK, and p-CREB expression. p-Akt expression was unaltered upon stimulation of lymphocytes with 17&#x03B2;-estradiol and/or adrenergic agonists.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>In silico model of adrenergic and estrogen signaling cascades in lymphocytes</title>
<p>The cross-talk between the adrenergic and estrogen-mediated signals result in specific immunomodulatory effects depending upon the estrogen concentration. The layout of the signaling pathway is elucidated from receptors to transduction into the cytosol and nuclear translocation of signaling molecules leading to specific outcomes.</p></caption>
<graphic xlink:href="353185_fig1.tif"/>
</fig>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2</label>
<caption><title>Alteration of signaling molecules with adrenergic agonists and 17&#x03B2;-estradiol treatment</title>
<p>While adrenergic agonists enhanced p-CREB and p-ERK expression (A), 17&#x03B2;-estradiol treatment alone (B) or with adrenergic agonists (C) enhanced cAMP, p-ERK and p-CREB expression.</p></caption>
<graphic xlink:href="353185_fig2.tif"/>
</fig>
</sec>
<sec id="s3b">
<label>3.2</label>
<title>17&#x03B2;-estradiol and adrenergic agonists decrease superoxides but enhance peroxynitrites in lymphocytes</title>
<p>Simulation of lymphocytes with adrenergic agonists terbutaline, clonidine, and phenylephrine (<xref ref-type="fig" rid="fig3">Fig. 3A</xref>), or 17&#x03B2;-estradiol (<xref ref-type="fig" rid="fig3">Fig. 3B</xref>) or both (<xref ref-type="fig" rid="fig3">Fig. 3C</xref>) similarly decrease production of superoxides and enhance production of peroxynitrite in lymphocytes within the 0.1 second time interval. State v/s time diagrams up to 0.3 seconds show decreased catalase (CAT) and superoxide dismutase (SOD) activities in all treatment groups.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3</label>
<caption><title>Adrenergic and estrogen signaling alter superoxides and peroxynitrites</title>
<p>Both adrenergic (A) and estrogen (B) signaling, alone or together (C) decrease superoxides and enhance production of peroxynitrite in lymphocytes.</p></caption>
<graphic xlink:href="353185_fig3.tif"/>
</fig>
</sec>
<sec id="s3c">
<label>3.3</label>
<title>17&#x03B2;-estradiol with or without adrenergic agonists increases CAT and SOD activities in lymphocytes but not adrenergic agonists alone</title>
<p>Simulation of lymphocytes with adrenergic agonists terbutaline, clonidine, and phenylephrine (<xref ref-type="fig" rid="fig4">Fig. 4A</xref>), or 17&#x03B2;-estradiol (<xref ref-type="fig" rid="fig4">Fig. 4B</xref>) or both (<xref ref-type="fig" rid="fig4">Fig. 4C</xref>) significantly alters CAT and SOD activities and production of peroxynitrites and superoxides within 3000 seconds of stimulation. State v/s time diagrams at 3000 seconds show significantly enhanced CAT and SOD activities upon stimulation with 17&#x03B2;-estradiol alone (<xref ref-type="fig" rid="fig4">Fig. 4B</xref>) or 17&#x03B2;-estradiol with adrenergic agonists (<xref ref-type="fig" rid="fig4">Fig. 4C</xref>). Stimulation with adrenergic agonists (<xref ref-type="fig" rid="fig4">Fig. 4A</xref>), or with 17&#x03B2;-estradiol alone (<xref ref-type="fig" rid="fig4">Fig. 4B</xref>) or 17&#x03B2;-estradiol with adrenergic agonists (<xref ref-type="fig" rid="fig4">Fig. 4C</xref>) significantly decreased peroxynitrite production similarly.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4</label>
<caption><title>Adrenergic and estrogen signaling alter superoxides and peroxynitrites differentially</title>
<p>Estrogen treatment alone (B) or on adrenergic agonist-treated lymphocytes (C) enhanced CAT and SOD activities and decreased peroxynitrite production. These effects were not observed on adrenergic stimulation alone (A).</p></caption>
<graphic xlink:href="353185_fig4.tif"/>
</fig>
</sec>
<sec id="s3d">
<label>3.4</label>
<title>17&#x03B2;-estradiol treatment alters cytokine production in lymphocytes stimulated with adrenergic agonists</title>
<p>Treatment with adrenergic agonists (<xref ref-type="fig" rid="fig5">Fig. 5A</xref>) does not alter IL-2 or IFN-&#x03B3; production in lymphocytes after 24 hours (86420 seconds) of treatment. However, treatment with 17&#x03B2;-estradiol alone (<xref ref-type="fig" rid="fig5">Fig. 5B</xref>) or 17&#x03B2;-estradiol with adrenergic agonists (<xref ref-type="fig" rid="fig5">Fig. 5C</xref>) significantly enhance IFN-&#x03B3; and IL-2 production after 24 hours of treatment.</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5</label>
<caption><title>17&#x03B2;-estradiol but not adrenergic stimulation alters cytokine production</title>
<p>Treatment with 17&#x03B2;-estradiol alone (B) or 17&#x03B2;-estradiol with adrenergic agonists (C) but not adrenergic agonists alone (A) significantly enhances IFN-&#x03B3; production after 24 hours of treatment.</p></caption>
<graphic xlink:href="353185_fig5.tif"/>
</fig>
</sec>
<sec id="s3e">
<label>3.5</label>
<title>17&#x03B2;-estradiol co-stimulation of lymphocytes stimulated with adrenergic agonists enhances proliferation dose-dependently</title>
<p>Adrenergic stimulation of lymphocytes significantly enhanced pro-apoptotic signals (<xref ref-type="fig" rid="fig6">Fig. 6A</xref>) above proliferation and favoured lymphocyte apoptosis. Co-stimulation with 17&#x03B2;-estradiol significantly enhanced proliferation and shifts the balance between pro-apoptotic and apoptotic signals (<xref ref-type="fig" rid="fig6">Fig. 6B</xref>). Ten-fold increase in 17&#x03B2;-estradiol concentration (<xref ref-type="fig" rid="fig6">Fig. 6C</xref>) further increases proliferation signals and reverses the balance in favor of proliferation over apoptosis after 24 hours.</p>
<fig id="fig6" position="float" fig-type="figure">
<label>Figure 6</label>
<caption><title>17&#x03B2;-estradiol enhances survival signals while adrenergic signals are pro-apoptotic</title>
<p>Adrenergic stimulation of lymphocytes favors lymphocyte apoptosis over survival (A) while treatment with estrogen alone (B) or co-stimulation with 17&#x03B2;-estradiol shifts the balance in favor survival signals (C).</p></caption>
<graphic xlink:href="353185_fig6.tif"/>
</fig>
</sec>
<sec id="s3f">
<label>3.6</label>
<title>Phenylephrine stimulation shows significantly increased sensitivity to IFN-&#x03B3; and p-CREB expression</title>
<p>Stimulation of lymphocytes with &#x03B1;1-AR agonist, phenylephrine, showed increased sensitivity to IFN-&#x03B3; (2X10<sup>&#x2212;25</sup>) but not IL-2 expression (<xref ref-type="fig" rid="fig7">Fig. 7A</xref>). Similarly, signaling molecules also showed altered sensitivities upon stimulation with phenylephrine, whereas p-CREB expression alone showed increased sensitivity of 2&#x00D7;10<sup>&#x2212;22</sup> (<xref ref-type="fig" rid="fig7">Fig. 7B</xref>).</p>
<fig id="fig7" position="float" fig-type="figure">
<label>Figure 7</label>
<caption><title>&#x03B1;1-AR stimulation in sensitive to IFN-&#x03B3; and p-CREB</title>
<p>Sensitivity analysis showed that al-AR stimulation was sensitive to IFN-&#x03B3; (2X10<sup>&#x2212;25</sup>; A) and p-CREB (2X10<sup>&#x2212;22</sup>; B).</p></caption>
<graphic xlink:href="353185_fig7.tif"/>
</fig>
</sec>
<sec id="s3g">
<label>3.7</label>
<title>Clonidine stimulation shows no alteration in sensitivity to cytokines or signaling molecules</title>
<p>There was no significant alterations in the sensitivities of IFN-&#x03B3; or IL-2 upon stimulation of lymphocytes with &#x03B1;2-AR agonist, clonidine (<xref ref-type="fig" rid="fig8">Fig. 8A</xref>). Similarly, sensitivities of signaling molecules p-ERK, p-CREB, p-Akt, and cAMP were not altered upon treatment of lymphocytes with clonidine (<xref ref-type="fig" rid="fig8">Fig. 8B</xref>).</p>
<fig id="fig8" position="float" fig-type="figure">
<label>Figure 8</label>
<caption><title>&#x03B1;2-AR stimulation is not sensitive to cytokine production or signaling molecules</title>
<p>Clonidine mediated signaling is not sensitive to cytokines (A) or signaling molecules (B).</p></caption>
<graphic xlink:href="353185_fig8.tif"/>
</fig>
</sec>
<sec id="s3h">
<label>3.8</label>
<title>Terbutaline stimulation of lymphocytes shows significantly enhanced sensitivity to IFN-&#x03B3;, p-ERK, and p-CREB expression</title>
<p>Stimulation of lymphocytes with &#x03B2;2-AR agonist, terbutaline, showed increased sensitivity to IFN-&#x03B3; (3.5&#x00D7;10<sup>&#x2212;24</sup>) but not IL-2 production (<xref ref-type="fig" rid="fig9">Fig. 9A</xref>). Similarly, signaling molecules also showed altered sensitivities upon stimulation with terbutaline, whereas p-ERK and p-CREB expression alone showed increased sensitivity of 7&#x00D7;10<sup>&#x2212;21</sup> (<xref ref-type="fig" rid="fig9">Fig. 9B</xref>).</p>
<fig id="fig9" position="float" fig-type="figure">
<label>Figure 9</label>
<caption><title>&#x03B2;2-AR stimulation of lymphocytes is sensitive to IFN-g, p-ERK and p-CREB expression</title>
<p>Terbutaline treatment-mediated signals are sensitive to IFN-&#x03B3; (3.5X10<sup>&#x2212;24</sup>; A) and pERK and p-CREB expression (7X10<sup>&#x2212;21</sup>; B).</p></caption>
<graphic xlink:href="353185_fig9.tif"/>
</fig>
</sec>
<sec id="s3i">
<label>3.9</label>
<title>17&#x03B2;-estradiol stimulation of lymphocytes shows significantly enhanced sensitivity to IFN-&#x03B3;, p-ERK, p-CREB and cAMP expression</title>
<p>There was a significant increase in the sensitivity of IFN-&#x03B3; (3.5X10<sup>&#x2212;16</sup>) upon stimulation of lymphocytes with 17&#x03B2;-estradiol (<xref ref-type="fig" rid="fig10">Fig. 10A</xref>). Also, there was a significantly high sensitivity to signaling molecules including p-ERK, p-CREB, and cAMP upon treatment of lymphocytes with 17&#x03B2;-estradiol (6X10<sup>&#x2212;15</sup>) (<xref ref-type="fig" rid="fig10">Fig. 10B</xref>).</p>
<fig id="fig10" position="float" fig-type="figure">
<label>Figure 10</label>
<caption><title>Estrogen receptor stimulation is sensitive to IFN-g, p-ERK, p-CREB and cAMP expression</title>
<p>17&#x03B2;-estradiol-mediated signals are sensitive to IFN-&#x03B3; (3.5X10<sup>&#x2212;16</sup>; A), p-ERK, p-CREB, and cAMP (6X10<sup>&#x2212;15</sup>; B).</p></caption>
<graphic xlink:href="353185_fig10.tif"/>
</fig>
</sec>
<sec id="s3j">
<label>3.10</label>
<title>Direct inhibition of ERK by NE</title>
<p>On the basis of the data obtained, the enzyme ERK (PDB ID: 2ERK; <italic>Rattus rattus;</italic> was inhibited by NE showing significant inhibitory activity. Analysis of the results obtained demonstrate that NE binds to the Catalytic residue Asp 147 and Glu 69; the residue that forms an ion pair with Lys 52 in the phosphate binding site of ERK with a Ki&#x003D;207.69 &#x03BC;M, bond distance of 2&#x0226; and an energy of &#x2212;5.02Kcal/mol (<xref ref-type="fig" rid="fig11a">Fig. 11A</xref>) and to Asp 177 which is close to the catalytic pocket with a Ki&#x003D;365.7&#x03BC;M and an energy of &#x2212;4.69Kcal/mol (<xref ref-type="fig" rid="fig11b">Fig. 11B</xref> and <xref rid="fig11c" ref-type="fig">11C</xref>).</p>
<fig id="fig11a" position="float" fig-type="figure">
<label>Figure 11</label>
<caption><title>Norepinephrine inhibits catalytic and phosphate binding residues of ERK</title>
<p>Norepinephrine inhibits ERK (PDB ID: 2ERK; <italic>Rattus rattus</italic>) by binding to the catalytic and phosphate binding residues (A), and residues close to the catalytic pocket (B and C).</p></caption>
<graphic xlink:href="353185_fig11a.tif"/>
</fig>
<fig id="fig11b" position="float" fig-type="figure">
<graphic xlink:href="353185_fig11b.tif"/>
</fig>
<fig id="fig11c" position="float" fig-type="figure">
<graphic xlink:href="353185_fig11c.tif"/>
</fig>
</sec>
<sec id="s3k">
<label>3.11</label>
<title>Direct inhibition of &#x03B2;2-AR by 17&#x03B2;-estradiol</title>
<p>17&#x03B2;-estradiol also bound to &#x03B2;2-AR receptor (PDB ID: 3SN6; <italic>Rattus norvegicus)</italic> at the Asp 173 residue with a Ki of 22.09 &#x03BC;M, bond distance of 1.99 &#x0226; and an energy of &#x2212;6.35Kcal/mol (<xref ref-type="fig" rid="fig12a">Fig. 12A</xref>), the Met 61 residue with a Ki&#x003D;11.0 &#x03BC;Mand an energy of &#x2212;6.76Kcal/mol(<xref ref-type="fig" rid="fig12b">Fig. 12B</xref>) and the Arg 314 residue with a Ki&#x003D; 8.77 &#x03BC;M, and an energy of &#x2212;6.9Kcal/mol(<xref ref-type="fig" rid="fig12c">Fig. 12C</xref>) indicating potent inhibitory effect.</p>
<fig id="fig12a" position="float" fig-type="figure">
<label>Figure 12</label>
<caption><title>17&#x03B2;-estradiol inhibits &#x03B2;2-AR binding to key residues</title>
<p>17&#x03B2;-estradiol inhibitsP2-AR receptor (PDB ID: 3SN6; <italic>Rattus norvegicus</italic>) by binding to the G-protein binding sites (A, B and C).</p></caption>
<graphic xlink:href="353185_fig12a.tif"/>
</fig>
<fig id="fig12b" position="float" fig-type="figure">
<graphic xlink:href="353185_fig12b.tif"/>
</fig>
<fig id="fig12c" position="float" fig-type="figure">
<graphic xlink:href="353185_fig12c.tif"/>
</fig>
</sec>
</sec>
<sec id="s4">
<label>4.0</label>
<title>Discussion</title>
<p>Immune functions of innate, humoral or cell-mediated origin are modulated by sympathetic signals and circulating hormone levels during health and disease in a dose and receptor-type-dependent manner [<xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c19">19</xref>]. <italic>In vitro</italic> studies from our laboratory have shown that adrenergic stimulation through &#x03B1;1-, &#x03B1;2&#x002D; or &#x03B2;2&#x002D; ARs using specific agonists non-specifically inhibit lymphoproliferation through distinct signaling pathways: &#x03B1;1-ARs mediated immunosuppressive effects by inhibiting IFN-&#x03B3; production, &#x03B1;2-AR activated the NF-&#x03BA;B, p-Akt and NO pathways and &#x03B2;2-AR activation involved IL-6, NO and NF-&#x03BA;B signaling cascades mediating immunosuppression [<xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c18">18</xref>]. On the other hand, treatment of lymphocytes with 17&#x03B2;-estradiol enhanced proliferation in a dose and receptor subtype specific manner through p-ERK, p-CREB and p-Akt involving IFN-&#x03B3; and compensatory mechanisms including anitioxidant enzymes [<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c20">20</xref>]. Our studies have shown that co-treatment of lymphocytes with 17&#x03B2;-estradiol and adrenergic agonists lead to 17&#x03B2;-estradiol-mediated over-ride of adrenergic immunosuppression in a dose-dependent, AR-subtype independent manner [<xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c18">18</xref>].</p>
<p>In the present study, we have modeled these signaling pathways <italic>in silico</italic> using MATLAB Simbiology toolbox. Due to difficulties in conducting the experiments using NE, the <italic>in vitro</italic> studies were conducted using receptor-specific agonists and antagonists. While these experiments are highly beneficial in elucidating the dose-dependent effects on specific adrenoceptor sub-types, they cannot be considered as absolute indicators of NE-mediated effects. This is because when NE is added to the cells, depending on its relative affinity for the individual receptor subtypes, it may bind proportionally to all the ARs triggering a wide variety of down-stream signals. The cumulative effects of these signals are likely to be different from the outcomes of receptor-subtype-specific signaling fates. In order to overcome this problem, the simulation model was constructed on the basis of the data obtained from <italic>in vitro</italic> studies and all three ARs studied were simultaneously activated to study the outcome. Based on previous findings, an attempt was made to incorporate cross-talks between these pathways by using common signaling molecule pools.</p>
<p>As expected, the simulation of lymphocytes with adrenergic agonists, phenylephrine, clonidine, and terbutaline enhanced p-CREB and p-ERK expression in accordance with classical adrenergic signaling cascades within a few milliseconds. 17&#x03B2;-estradiol behaved similarly in the presence and absence of adrenergic agonists enhancing cAMP, p-ERK, and p-CREB expression suggesting that activation of cAMP may be crucial to 17&#x03B2;-estradiol-mediated over-ride of adrenergic immunosuppression.</p>
<p>A significant role is played by compensatory mechanisms such as antioxidant enzyme apart from signaling molecules, to influence the proliferative/apoptotic milieu of a cell by balancing free radical load including superoxides and peroxynitrites to name a few. These free radicals released as by-products following immune responses or during neurotransmitter release in secondary lymphoid organs may accumulate over the years and contribute to denervation of sympathetic noradrenergic fibers leading to impaired neuroendocrine-immune homeostasis setting the stage for age-associated diseases [<xref ref-type="bibr" rid="c7">7</xref>]. Studies from our lab and others have documented ER-subtype dependent increase in SOD and GPx activities in lymphocytes stimulated with estrogen [<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c21">21</xref>&#x2013;<xref ref-type="bibr" rid="c24">24</xref>]. Adrenergic stimulation also enhanced SOD and catalase activities <italic>in vitro</italic> which were suppressed upon coincubation with 17&#x03B2;-estradiol indicating cross-talk between the two pathways leading to diminutive effects [<xref ref-type="bibr" rid="c18">18</xref>]. Along these lines, previous studies have implicated the involvement of PKA and ERK pathways, which when inhibited, reversed terbutaline-mediated increase in SOD and CAT activities. It is possible that these signaling molecules play a regulatory role in the expression and activity of these enzymes, thereby, exerting immunomodulatory effects [<xref ref-type="bibr" rid="c25">25</xref>, <xref ref-type="bibr" rid="c26">26</xref>]. In our model, adrenergic activation, 17&#x03B2;-estradiol treatment, and their co-treatment decrease superoxide formation but enhance peroxynitrites, although 17&#x03B2;-estradiol treatment or co-treatment alone was accompanied by an induction of SOD and CAT activities within the 3000 second time frame.</p>
<p>Cytokines play a crucial role in influencing immune functions thereby affecting survival/apoptosis. Previously we have shown that while activation of &#x03B1;1-ARs decrease IFN-&#x03B3; and increase IL-2 production, &#x03B1;2&#x002D; and &#x03B2;2-AR activation did not alter both IFN-&#x03B3; and IL-2 production. Co-activation of all three signals show that adrenergic stimulation does not alter IL-2 or IFN-&#x03B3; production in lymphocytes after 24 hours (86420 seconds) of treatment. However, treatment with 17&#x03B2;-estradiol alone or 17&#x03B2;-estradiol with adrenergic agonists significantly enhance IFN-&#x03B3; production alone after 24 hours of treatment. We have reported dose-dependent increase in IFN-&#x03B3; production with 17&#x03B2;-estradiol alone or co-treated with &#x03B1;1&#x002D; and &#x03B2;2-AR agonists. In agreement with these findings, sensitivity analysis show that stimulation of lymphocytes with &#x03B1;1-AR agonist, phenylephrine, showed increased sensitivity to IFN-&#x03B3; (2&#x00D7;10<sup>&#x2212;25</sup>) and p-CREB expression 2X10<sup>&#x2212;22</sup> while &#x03B2;2-AR agonist terbutaline showed increased sensitivity to IFN-&#x03B3; (3.5X10<sup>&#x2212;24</sup>), p-ERK and p-CREB expression 7&#x00D7;10<sup>&#x2212;21</sup>. Interestingly 17&#x03B2;-estradiol signaling showed the highest sensitivity to IFN-&#x03B3; (3.5&#x00D7;10<sup>&#x2212;16</sup>), p-ERK, p-CREB, and cAMP (6&#x00D7;10<sup>&#x2212;15</sup>) suggesting a probable cause in the dynamics of 17&#x03B2;-estradiol-mediated signals that predispose it to over-ride adrenergic signals.</p>
<p>In order to assess the likely effects of the signals and their cross-talks on proliferation, endpoint signals were classified as either pro-apoptotic or survival signals. Plots obtained at the end of 72 hours indicate that while adrenergic stimulation was predominantly pro-apoptotic signals, 17&#x03B2;-estradiol signals were pro-survival. Dose-dependent role of 17&#x03B2;-estradiol could be seen by increasing the 17&#x03B2;-estradiol concentration by 10-fold leading to further increase in proliferation signals reversing the balance in favor of proliferation over apoptosis after 72 hours. This is in accordance with the <italic>in vitro</italic> evidence generated in previous studies where all the adrenergic agonists decreased proliferation while 17&#x03B2;-estradiol played a dose-dependent role in increasing proliferation of lymphocytes.</p>
<p>Finally, docking studies show that apart from modulating signaling mechanisms, NE can directly inhibit ERK and estrogen can directly bind to key residues on &#x03B2;<sub>2</sub>-AR inhibiting its subsequent signal transduction processes. Thus, <italic>in silico</italic> modeling of estrogen and adrenergic signaling pathways in lymphocytes implicates the involvement of cAMP and ERK as key regulatory molecules that influence the cross-talk between the signaling cascades mediating immunomodulatory effects. Modeling estrogen and adrenergic stimulation-mediated signals will help us to understand variations in the expression of downstream molecular markers with age&#x002D; and disease-associated variations in kinetic parameters and concentrations and thereby providing an effective tool for understanding the alterations in the cross talk between the pathways in health, aging, and diseases.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgement</title>
<p>Supported by the Department of Science and Technology (F.No. SR/SO/HS-46/2007 and IFA15/LSBM-154), Government of India, New Delhi.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="book"><string-name><surname>Ader</surname> <given-names>R</given-names></string-name>, <string-name><surname>Felten</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>N</given-names></string-name>. <source>Psychoneuroimmunology</source>. <edition>3rd Edition</edition>. <publisher-name>Academic Press</publisher-name>; <publisher-loc>San Diego, CA</publisher-loc>. <year>2001</year>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Priyanka</surname> <given-names>HP</given-names></string-name>, <string-name><surname>Sharma</surname> <given-names>U</given-names></string-name>, <string-name><surname>Gopinath</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sharma</surname> <given-names>V</given-names></string-name>, <string-name><surname>Hima</surname> <given-names>L</given-names></string-name>, <string-name><surname>ThyagaRajan</surname> <given-names>S</given-names></string-name>. <article-title>Menstrual cycle and reproductive aging alters immune reactivity, NGF expression, antioxidant enzyme activities, and intracellular signaling pathways in the peripheral blood mononuclear cells of healthy women</article-title>. <source>Brain Behavior Immunity</source>. <year>2013</year>; <volume>32</volume>: <fpage>131</fpage>&#x2013;<lpage>143</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>ThyagaRajan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Priyanka</surname> <given-names>HP</given-names></string-name>. <article-title>Bidirectional communication between the neuroendocrine system and the immune system: relevance to health and diseases</article-title>. <source>Annals of Neurosciences</source>. <year>2011</year>; <volume>19</volume>: <fpage>40</fpage>&#x2013;<lpage>46</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Priyanka</surname> <given-names>HP</given-names></string-name>, <string-name><surname>Krishnan</surname> <given-names>HC</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>RV</given-names></string-name>, <string-name><surname>Hima</surname> <given-names>L</given-names></string-name>, <string-name><surname>ThyagaRajan</surname> <given-names>S</given-names></string-name>. <article-title>Estrogen modulates in vitro T cell responses in a concentration&#x002D; and receptor dependent manner: effects on intracellular molecular targets and antioxidant enzymes</article-title>. <source>Molecular Immunology</source>. <year>2013</year>; <volume>56</volume>: <fpage>328</fpage>&#x2013;<lpage>339</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="book"><string-name><surname>Lu</surname> <given-names>JKH</given-names></string-name>. <chapter-title>Changes in ovarian function and gonadotropin and prolactin secretion in aging female rats</chapter-title>. In: <person-group person-group-type="editor"><string-name><surname>Meites</surname> <given-names>J</given-names></string-name> (Ed)</person-group>. <source>Neuroendocrinology of Aging</source>, (pp.<fpage>103</fpage>&#x2013;<lpage>122</lpage>), <publisher-loc>Plenum, New York</publisher-loc>. <year>1983</year>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Wise</surname> <given-names>PM.</given-names></string-name> <article-title>Alterations in the proestrous pattern of median eminence LHRH, serum LH, FSH, estradiol and progesterone concentrations in middle-aged rats</article-title>. <source>Life Sciences</source>. <year>1982</year>; <volume>31</volume>: <fpage>165</fpage>&#x2013;<lpage>173</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>ThyagaRajan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Madden</surname> <given-names>KS</given-names></string-name>, <string-name><surname>Teruya</surname> <given-names>B</given-names></string-name>, <string-name><surname>Stevens</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Felten</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Bellinger</surname> <given-names>DL.</given-names></string-name> <collab>(2011)</collab>. <article-title>Age-associated alterations in sympathetic noradrenergic innervation of primary and secondary lymphoid organs in female Fischer 344 rats</article-title>. <source>Journal of Neuroimmunology</source>. <year>2011</year>; <volume>233</volume>: <fpage>54</fpage>&#x2013;<lpage>64</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Lang</surname> <given-names>TJ.</given-names></string-name> <article-title>Estrogen as an immunomodulator</article-title>. <source>Clinical Immunology</source>. <year>2004</year>; <volume>113</volume>: <fpage>224</fpage>&#x2013;<lpage>230</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="confproc"><string-name><surname>Meites</surname> <given-names>J.</given-names></string-name> <source>Aging: hypothalamic catecholamines, neuroendocrine-immuneinteractions, and dietary restriction</source>. <conf-name>Proceedings of the Society for Experimental Biology and Medicine</conf-name>. <year>1990</year>; <volume>195</volume>: <fpage>304</fpage>&#x2013;<lpage>311</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Felten</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Felten</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Bellinger</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Carlson</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Ackerman</surname> <given-names>KD</given-names></string-name>, <string-name><surname>Madden</surname> <given-names>KS</given-names></string-name>, <string-name><surname>Olschowki</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Livnat</surname> <given-names>S.</given-names></string-name> <article-title>Noradrenergic sympathetic neural interactions with the immune system: structure and function</article-title>. <source>Immunological Reviews</source>. <year>1987</year>; <volume>100</volume>: <fpage>225</fpage>&#x2013;<lpage>260</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Madden</surname> <given-names>KS.</given-names></string-name> <article-title>Catecholamines, sympathetic innervation, and immunity</article-title>. <source>Brain Behavior Immunity</source>, <year>2003</year>; <volume>17</volume>: <fpage>S5</fpage>&#x2013;<lpage>S10</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Madden</surname> <given-names>KS</given-names></string-name>, <string-name><surname>Felten</surname> <given-names>DL.</given-names></string-name> <article-title>Experimental basis for neural-immune interactions</article-title>. <source>Physiological Reviews</source>. <year>1995</year>; <volume>75</volume>: <fpage>77</fpage>&#x2013;<lpage>106</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Nance</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Sanders</surname> <given-names>VM.</given-names></string-name> <article-title>Autonomic innervation and regulation of the immune system (1987-2007)</article-title>. <source>Brain Behavior Immunity</source>. <year>2007</year>; <volume>21</volume>: <fpage>736</fpage>&#x2013;<lpage>774</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Cunningham</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gilkeson</surname> <given-names>G.</given-names></string-name> <article-title>Estrogen receptors in immunity and autoimmunity</article-title>. <source>Clinical Reviews in Allergy and Immunology</source>. <year>2011</year>; <volume>40</volume>: <fpage>66</fpage>&#x2013;<lpage>73</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Bao</surname> <given-names>JY</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>F</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>YP</given-names></string-name>, <string-name><surname>Qiu</surname> <given-names>YH.</given-names></string-name> <article-title>Expression of alpha-AR subtypes in T lymphocytes and role of the alpha-ARs in mediating modulation of T cell function</article-title>. <source>Neuro immunomodulation</source>. <year>2007</year>; <volume>14</volume>: <fpage>344</fpage>&#x2013;<lpage>353</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Sanders</surname> <given-names>VM.</given-names></string-name> <article-title>The beta2-adrenergic receptor on T and B lymphocytes: do we understand it yet</article-title>? <source>Brain Behavior Immunity</source>. <year>2012</year>; <volume>26</volume>: <fpage>195</fpage>&#x2013;<lpage>200</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Priyanka</surname> <given-names>HP</given-names></string-name>, <string-name><surname>ThyagaRajan</surname> <given-names>S.</given-names></string-name> <article-title>Selective modulation of lymphoproliferation and cytokine production via intracellular signaling targets by &#x03B1;1-and &#x03B1;2-adrenoceptors and estrogen in splenocytes</article-title>. <source>International Immunopharmacology</source>. <year>2013</year>; <volume>17</volume>: <fpage>774</fpage>&#x2013;<lpage>784</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Priyanka</surname> <given-names>HP</given-names></string-name>, <string-name><surname>Pratap</surname> <given-names>UP</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>RV</given-names></string-name>, <string-name><surname>ThyagaRajan</surname> <given-names>S.</given-names></string-name> <article-title>Estrogen modulates &#x03B2;2-adrenoceptor-induced cell-mediated and inflammatory immune responses through ER-&#x03B1; involving distinct intracellular signaling pathways, antioxidant enzymes, and nitric oxide</article-title>. <source>Cellular Immunology</source>. <year>2014</year>; <volume>292</volume>: <fpage>1</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Bellinger</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Lorton</surname> <given-names>D.</given-names></string-name> <article-title>Autonomic regulation of cellular immune function</article-title>. <source>Autonomic Neuroscience</source>. <year>2014</year>; <volume>182</volume>: <fpage>15</fpage>&#x2013;<lpage>41</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Kale</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mohanty</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mishra</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pratap</surname> <given-names>UP</given-names></string-name>, <string-name><surname>Priyanka</surname> <given-names>HP</given-names></string-name>, <string-name><surname>ThyagaRajan</surname> <given-names>S.</given-names></string-name> <article-title>Estrogen modulates neural-immune interactions through intracellular signaling pathways and antioxidant enzyme activity in the spleen of middle-aged ovariectomized female rats</article-title>. <source>Journal of Neuroimmunology</source>. <year>2014</year>; <volume>267</volume>: <fpage>7</fpage>&#x2013;<lpage>15</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Abbas</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Elsamanoudy</surname> <given-names>AZ.</given-names></string-name> <article-title>Effects of 17&#x03B2;-estradiol and antioxidant administration on oxidative stress and insulin resistance in ovariectomized rats</article-title>. <source>Canadian Journal of Physiology and Pharmacology</source>. <year>2011</year>; <volume>89</volume>: <fpage>497</fpage>&#x2013;<lpage>504</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Brann</surname> <given-names>D</given-names></string-name>, <string-name><surname>Raz</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>R</given-names></string-name>, <string-name><surname>Vadlamudi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Q.</given-names></string-name> <article-title>Oestrogen signalling and neuroprotection in cerebral ischaemia</article-title>. <source>Journal of Neuroendocrinology</source>. <year>2012</year>; <volume>24</volume>: <fpage>34</fpage>&#x2013;<lpage>47</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Simpkins</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Green</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Gridley</surname> <given-names>KE.</given-names></string-name> <article-title>Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer&#x2019;s disease</article-title>. <source>The American Journal of Medicine</source>. <year>1997</year>; <volume>103</volume>: <fpage>S19</fpage>&#x2013;<lpage>S25</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Stirone</surname> <given-names>C</given-names></string-name>, <string-name><surname>Duckles</surname> <given-names>SP</given-names></string-name>, <string-name><surname>Krause</surname> <given-names>DN</given-names></string-name>, <string-name><surname>Procaccio</surname> <given-names>V.</given-names></string-name> <article-title>Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels</article-title>. <source>Molecular Pharmacology</source>. <year>2005</year>; <volume>68</volume>: <fpage>959</fpage>&#x2013;<lpage>965</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Sugino</surname> <given-names>N</given-names></string-name>, <string-name><surname>Karube-Harada</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sakata</surname> <given-names>A.</given-names></string-name> <article-title>Different mechanisms for the induction of copper-zinc superoxide dismutase and manganese superoxide dismutase by progesterone in human endometrial stromal cells</article-title>. <source>Human Reproduction</source>. <year>2002</year>; <volume>17</volume>: <fpage>1709</fpage>&#x2013;<lpage>1714</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Yano</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yano</surname> <given-names>N.</given-names></string-name> <article-title>Regulation of catalase enzyme activity by cell signaling molecules</article-title>. <source>Molecular and Cellular Biochemistry</source>. <year>2002</year>; <volume>240</volume> (<issue>1-2</issue>): <fpage>119</fpage>&#x2013;<lpage>130</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Ricci</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bronzetti</surname> <given-names>E</given-names></string-name>, <string-name><surname>Conterno</surname> <given-names>A</given-names></string-name>, <string-name><surname>Greco</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mulatero</surname> <given-names>P</given-names></string-name>, <string-name><surname>Schena</surname> <given-names>M</given-names></string-name>, <string-name><surname>Schiavone</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tayebati</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Veglio</surname> <given-names>F</given-names></string-name>, <string-name><surname>Amenta</surname> <given-names>F.</given-names></string-name> <article-title>Alpha1-adrenergic receptor subtypes in human peripheral blood lymphocytes</article-title>. <source>Hypertension</source>. <year>1999</year>; <volume>33</volume>(<issue>2</issue>): <fpage>708</fpage>&#x2013;<lpage>712</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Titinchi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Clark</surname> <given-names>B.</given-names></string-name> <article-title>Alpha 2-adrenoceptors in human lymphocytes: direct characterisation by [3H] yohimbine binding</article-title>. <source>Biochemical and Biophysical Research Communications</source>. <year>1984</year>; <volume>31</volume>: <fpage>1</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Hataoka</surname> <given-names>I</given-names></string-name>, <string-name><surname>Okayama</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sugi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Inoue</surname> <given-names>H</given-names></string-name>, <string-name><surname>Takishima</surname> <given-names>T</given-names></string-name>, <string-name><surname>Shirato</surname> <given-names>K.</given-names></string-name> <article-title>Decrease in beta-adrenergic receptors of lymphocytes in spontaneously occurring acute asthma</article-title>. <source>Chest</source>. <year>1993</year>; <volume>104</volume>: <fpage>508</fpage>&#x2013;<lpage>514</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>van den Meiracker</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Man in&#x2019;t Veld</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Boomsma</surname> <given-names>F</given-names></string-name>, <string-name><surname>Fischberg</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Molinoff</surname> <given-names>PB</given-names></string-name>, <string-name><surname>Schalekamp</surname> <given-names>MA.</given-names></string-name> <article-title>Hemodynamic and beta-adrenergic receptor adaptations during longterm beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients</article-title>. <source>Circulation</source>. <year>1989</year>; <volume>80</volume> (<issue>4</issue>): <fpage>903</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Bongioanni</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lombardo</surname> <given-names>F</given-names></string-name>, <string-name><surname>Fioretti</surname> <given-names>C</given-names></string-name>, <string-name><surname>Meucci</surname> <given-names>G.</given-names></string-name> <article-title>T-lymphocyte immunointerferon receptors in patients with multiple sclerosis</article-title>. <source>Journal of Neurology</source>. <year>1996</year>; <volume>243</volume>: <fpage>605</fpage>&#x2013;<lpage>610</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Feng</surname> <given-names>S.</given-names></string-name> <article-title>Estrogen receptor content of peripheral blood lymphocytes in patients with SLE</article-title>. <source>Zhonghua Yi Xue Za Zhi</source>. <year>1991</year>; <volume>71</volume>(<issue>2</issue>): <fpage>1</fpage>&#x2013;<lpage>3</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>